Bioscicon, Inc.

Rockville, MD 20850

SBIR Award Summary

Total Number of Awards 4
Total Value of Awards $819K
First Award Date 05/15/00
Most Recent Award Date 07/01/02

Key Personnel

Last Name Name Awards Contact
Markovic Nenad Markovic 1
Markovic Olivera Markovic 3

4 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/02 - 06/30/04

DESCRIPTION (provided by applicant): CAP-PAP Test (further: CPT) is a double-staining, single-slide method for cervical cancer primary screening based on a new biological marker of cervical dysplasia (US patent No. 6,143,512 of November 7, 2000). In phase-1 study (SBIR-NCI-NIH award No. 1R43CA86767-01) the met...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/15/02 - 03/31/03

The CAP-PAP test is a single-slide, double-staining, in vitro method for labeling dysplastic cervical cells on Pap smears (USPTO#6, 143, 512). A recently completed clinical laboratory trial (1R43CA86767-01) has shown that this test is easily applicable in a routine cytopathology laboratory for cervical cancer screening. The safety of the new met...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/20/01 - 06/30/02

DESCRIPTION (provided by applicant): CAP-PAP Test (further: CPT) is a double-staining, single-slide method for cervical cancer primary screening based on a new biological marker of cervical dysplasia (US patent No. 6,143,512 of November 7, 2000). In phase-1 study (SBIR-NCI-NIH award No. 1R43CA86767-01) the met...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/15/00 - 04/30/01

BioSciCon is in possession of a patent application for a new method that could be developed into an in vitro diagnostic medical device for primary cervical cancer screening (CCC). This application is for a phase I/II clinical laboratory trial to study how the new test can increase sensitivity of cytotechnologists---- performing primary screenin...